Investor Presentation Q1 2023

41 Investor presentation First three months of 2023 Novo Nordisk has 54% of the global GLP-1 market, while GLP-1 penetration of diabetes volume varies across regions 80% 60% 40% 20% Novo NordiskⓇ GLP-1 market growth and Novo Nordisk market share GLP-1 share of total estimated diabetes prescriptions¹ is 5% Million prescriptions¹ 250 70% 67% Global: 5% 200 56% Global: 1% 54% 150 100 50 0% 0 Feb Feb 2018 2020 2023 NN market share -Market growth NN share of growth NN growth GLP-1 Source: IQVIA MAT value (spot rate), Feb 2023 SGLT-2i DPP-4i Insulin 2023 Trad. OAD GLP-1 share of estimated diabetes prescriptions 1 The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full- year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions Source: IQVIA MAT volume (Spot rate), Feb 2023

View entire presentation